SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides ...

"James brings the right experience in the biopharma business as we’re accelerating the advancement of multiple clinical ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine New antiviral drugs in development could offer the ...

As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. In this podcast, Anil Diwan, President and Executive Chairman of ...

Detailed price information for Cocrystal Pharma Inc (COCP-Q) from The Globe and Mail including charting and trades.

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

Researchers at the Nanoscience Initiative, Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have made what they describe as a breakthrough in the fight against viral diseases, ...

Headshot of Sumit Chanda standing outside Scripps Research Institute. Sumit Chanda has dedicated his career to antiviral drug research. Credit: Courtesy of the Chanda Lab The US National Institutes of ...

Okay. We are ready to get started. So good afternoon, everyone, and thank you for joining us today for our Virtual Investor Closing Bell segment. My name is Jenene Thomas, I am CEO of JTC IR, and I ...

A new oral antiviral drug candidate has been developed for the treatment of diseases caused by orthoparamyxoviruses, such as measles and Croup syndrome, according to a study published by researchers ...

Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA ...